Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 1.00 |
| ▸ | AR | P10275 | 5/20 | 0.77 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7181681 | 1.00 | VDR (1.00) | VDRARHDAC6HDAC3HDAC1 | |
| SCHEMBL16183037 | 0.94 | VDR (0.89) | VDRARHDAC6HDAC3HDAC1 | |
| SCHEMBL16183080 | 0.94 | VDR (0.89) | VDRARHDAC6HDAC3HDAC1 | |
| SCHEMBL16177773 | 0.94 | VDR (0.89) | VDRARHDAC6HDAC3 | |
| SCHEMBL2944811 | 0.93 | VDR (0.87) | VDRARHDAC6HDAC3 | |
| SCHEMBL20059753 | 0.93 | VDR (0.87) | VDRARHDAC6HDAC3HDAC1 | |
| SCHEMBL15059136 | 0.93 | VDR (0.87) | VDRARHDAC6HDAC3 | |
| SCHEMBL2946219 | 0.92 | VDR (0.85) | VDRARHDAC6HDAC3 | |
| SCHEMBL14254352 | 0.92 | VDR (0.85) | VDRARHDAC6HDAC3HDAC1 | |
| SCHEMBL2973082 | 0.92 | VDR (0.85) | VDRARHDAC6HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376264-B2 | Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376264-B2 | Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment | BRD9, BRD2, BRD3 | VDR 5/4885AR 1711/4885HDAC6 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.